Literature DB >> 6643338

Interactions of antibiotics and phagocytes.

W L Hand, N L King-Thompson, T H Steinberg.   

Abstract

Optimal therapy of infections due to organisms capable of surviving within phagocytes would include use of antimicrobials that penetrate phagocytic cells and inactivate intracellular organisms. To establish those characteristics of drug and cell that mediate the antibiotic-phagocyte interaction, we have studied the uptake of radiolabelled antibiotics by rabbit alveolar macrophages (AM), human AM from smokers and non-smokers, and human polymorphonuclear leukocytes (PMN). Relative entries of drug groups into the three types of phagocytic cells were similar. Penicillin G and cephalosporin antibiotics were taken up poorly by phagocytes. Lipid-soluble antibiotics, such as rifampicin and chloramphenicol, were concentrated several-fold (2-5) by phagocytes. Ethambutol, erythromycin and clindamycin were concentrated many-fold (5-50) by phagocytic cells. Human AM of smokers accumulated certain antibiotics more avidly than AM of non-smokers. Clindamycin entry into phagocytes was shown to be an active, energy-requiring process, mediated by the nucleoside transport system. Ingestion of microbial particles by PMN stimulated transport of both clindamycin and nucleoside (adenosine) into the cell.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6643338     DOI: 10.1093/jac/12.suppl_c.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

Review 1.  Pulmonary disposition of antimicrobial agents: methodological considerations.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 2.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

3.  Subinhibitory antimicrobial concentrations: A review of in vitro and in vivo data.

Authors:  G G Zhanel; D J Hoban; G K Harding
Journal:  Can J Infect Dis       Date:  1992-07

4.  Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.

Authors:  J Blais; C Tardif; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

5.  Intracellular activity of tosufloxacin (T-3262) against Salmonella enteritidis and ability to penetrate into tissue culture cells of human origin.

Authors:  T Noumi; N Nishida; S Minami; Y Watanabe; T Yasuda
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection.

Authors:  M R Scavizzi; J M Alonso; A M Philippon; A M Jupeau-Vessieres; A Guiyoule
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

7.  Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection.

Authors:  B C Lemaitre; D A Mazigh; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan-Levasseur; E Dournon; G Dameron; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 9.  Intracellular distribution and activity of antibiotics.

Authors:  P M Tulkens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

10.  Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis.

Authors:  Florian Tomaselli; Peter Dittrich; Alfred Maier; Michael Woltsche; Veronika Matzi; Johannes Pinter; Stephan Nuhsbaumer; Hans Pinter; Josef Smolle; Freyja M Smolle-Jüttner
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.